A new technology is disrupting the economy. Even experts don’t entirely understand how it works, its full range of uses and ...

2024 was another banner year for GLP-1 receptor agonists (GLP-1RAs) on multiple fronts ... Commercially, the most successful one so far is semaglutide, sold under the brand name Wegovy or Ozempic ...

Not long after the FDA wrapped its preliminary investigation of GLP-1 receptor agonists and suicidal thoughts or actions, the ...

Anti-obesity medication use was associated with reduced alcohol consumption among patients in a telehealth medical weight ...

GLP-1 modulators, formally known as glucagon-like peptide-1 receptor agonists ... Newer drugs such as liraglutide, ...

Undiagnosed or untreated EPI could result in muscle loss since the patient isn’t absorbing the necessary nutrients.

Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...

Hims & Hers Health, Inc. (NYSE: HIMS) are trading lower Thursday. The U.S. Food and Drug Administration (FDA) issued a new decision regarding the status of tirzepatide injection shortages, which have ...

At present, the FDA has approved just three GLP-1 medications for weight control: tirzepatide, liraglutide, and semaglutide ... is a thyroid hormone receptor beta agonist for lipid and metabolic ...

AS GLP-1 AGONISTS soar in popularity—about 12 percent of the U.S. population has tried one, most often Ozempic or Wegovy (semaglutide)—researchers are scrambling to understand their potential ...

GLP-1 receptor agonists emerge as promising therapies ... Several GLP-1RAs, including liraglutide, semaglutide, and tirzepatide, have been evaluated in clinical trials for their efficacy in ...